Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies

Clinical Cancer Research

Volumn 3, Issue 7, 1997, Pages 1077-1086

  Goss, Paul E ^a,c   Reid, Caroline L ^a   Bailey, Dennis ^a   Dennis, James W ^b,c  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c Inflazyme Pharmaceuticals Ltd   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SWAINSONINE;

ADRENAL CANCER; ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MALE; MELANOMA; MESOTHELIOMA; METASTASIS INHIBITION; PANCREAS CANCER; PARESTHESIA; PHARYNX CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VERTIGO;

ADULT; AGED; ALPHA-MANNOSIDASE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASPARTATE AMINOTRANSFERASES; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MANNOSIDASES; MICE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASMS; OLIGOSACCHARIDES; SWAINSONINE;

EID: 0030878261     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Varki, A., Hooshmand, F., Diaz, S., Varki, N. M., and Hedrick, S. M. Developmental abnormalities in transgenic mice expressing a sialic acid-specific 9-O-acetylesterase. Cell, 65: 65-74, 1991.
2. Varki, A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology, 3: 97-130, 1993.
3. Dennis, J. W. Changes in glycosylation with malignant transformation and tumor progression. In: M. Fukuda (ed.), Cell Surface Carbohydrates and Cell Development, pp. 161-194, Boca Raton: CRC Press, 1991.
4. Kornfeld, R., and Kornfeld, S. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem., 54: 631-664, 1985.
5. Schachter, H. Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. Biochem. Cell. Biol., 64: 163-181, 1986.
6. Roth, J. Subcellular organization of glycosylation in mammalian cells. Biochim. Biophys. Acta, 7: 405-436, 1987.
7. Yamashita, K., Tachibana, Y., Ohkura, T., and Kobata, A. Enzymatic basis for the structural changes of asparagine-linked sugar chains of membrane glycoproteins of baby hamster kidney cells induced by polyoma transformation. J. Biol. Chem., 260: 3963-3969, 1985.
8. Dennis, J. W., Kosh, K., Bryce, D-M., and Breitman, M. Oncogenes conferring metastatic potential induce increased branching of Asn-linked oligosaccharides in rat2 fibroblasts. Oncogene, 4: 853-860, 1989.
9. Miyoshi, E., Nishikawa, A., Ihara, Y., Gu., J., Sugiyama, T., Hayashi, N., Fusamoto, H., Kamada, T., and Taniguchi, N. N-Acetylglucosaminyltransferase III and V messenger RNA levels in LEC rats during hepatocarcinogenesis. Cancer Res., 53: 3899-3902, 1993.
10. Easton, E. W., Blokland, I., Geldof, A. A., Rao, B. R., and van den Eijnden, D. H. The metastatic potential of rat prostate tumor variant R3327-MatLyLu is correlated with an increased activity of N-acetylglucosaminyltransferase III and V. FEBS Lett., 308: 46-49, 1992.
11. Dennis, J. W., Kosh, K., Bryce, D-M., and Breitman, M. Oncogenes conferring metastatic potential induce increased branching of Asn-linked oligosaccharides in rat2 fibroblasts. Oncogene, 4: 853-860, 1989.
12. Dennis, J. W., Laferte, S., Waghorne, C., Breitman, M. L., and Kerbel, R. S. β1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science (Washington DC), 236: 582-585, 1987.
13. Dennis, J. W., and Laferte, S. Oncodevelopmental expression of GlcNAcβ1-6Manα1-6Manβ1 branched asparagine-linked oligosaccharides in human breast carcinomas. Cancer Res., 49: 945-950, 1989.
14. Fernandes, B., Sagman, U., Auger, M., Demetrio, M., and Dennis, J. W. β1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res., 57: 718-723, 1991.
15. Dennis, J. W. Effects of swainsonine and polyinosinic-polycytidylic acid on murine tumor cell growth and metastasis. Cancer Res., 46: 5131-5136, 1986.
16. Humphries, M. J., Matsumoto, K., White, S. L., and Olden, K. Oligosaccharide modification by swainsonine treatment inhibits pulmonary colonization by B16-F10 murine melanoma cells. Proc. Natl. Acad. Sci. USA, 83: 1752-1756, 1986.
17. Pulverer, G., Beuth, J., Ko, H. L., Yassin, A., Ohshima, Y., Roszkowski, K., and Uhlenbruck, G. Glycoprotein modifications of sarcoma L-1 tumor cells by tunicamycin, swainsonine, bromoconduritol or 1-deoxynorjirimycin treatment inhibits their metastatic lung colonization in Balb/c mice. J. Cancer Res. Clin. Oncol., 114: 217-220, 1988.
18. Humphries, M. J., Matsumoto, K., White, S. L, and Olden, K. Inhibition of experimental metastasis by castanospermine in mice: blockage of two distinct stages of tumor colonization by oligosaccharide processing inhibitors. Cancer Res., 46: 5215-5222, 1986.
19. Colegate, S. M., Huxtable, C. R., and Dorling, P. R. A spectroscopic investigation of swainsonine: an α-mannosidase inhibitor isolated from Swainsona canescens. Aust. J. Chem., 32: 2257-2264, 1979.
20. Molyneux, R. J., and James, L. F. Loco intoxication: indolizidine alkaloid of spotted locoweed. Science (Washington DC), 216: 190-191, 1981.
21. Yagel, S., Feinmesser, R., Waghorne, C., Lala, P. K., Breitman, M. L., and Dennis, J. W. Evidence that β1-6 branched Asn-linked oligosaccharides on metastatic tumor cells facilitate invasion of basement membranes. Int. J. Cancer, 44: 685-690, 1989.
22. Seftor, R. E. B., Seftor, E. A., Grimes, W. J., Liotta, L. A., Stetler-Stevenson, W. G., Welch, D. R., and Hendrix, M. J. C. Human melanoma cell invasion is inhibited in vitro by swainsonine and deoxymannojirimycin with a concomitant decrease in collagenase IV expression. Melanoma Res., 1: 43-54, 1991.
23. Humphries, M. J., Matsumoto, K., White, S. L., Molyneux, R. J., and Olden, K. Augmentation of murine natural killer cell activity by swainsonine, a new antimetastatic immunomodulator. Cancer Res., 48: 1410-1415, 1988.
24. Humphries, M. J., Matsumoto, K., White, S. L., Molyneux, R. J., and Olden, K. An assessment of the effects of swainsonine on survival of mice injected with B16-F10 melanoma cells. Clin. Exp. Metastasis, 8: 89-102, 1990.
25. Dennis, J. W., Koch, K., and Beckner, D. Inhibition of human HT29 colon carcinoma growth in vitro and in vivo by swainsonine and human interferon-α2. J. Natl. Cancer Inst., 81: 1028-1033, 1989.
26. Kino, T., Inamura, N., Nakahara, K., Kiyoto, S., Goto, T., Terano, H., Kohsaka, M., Oaki, H., and Imanaka, H. Effect of swainsonine on mouse immunodeficient system and experimental murine tumor. J. Antibiot., 38: 936-940, 1985.
27. Dennis, J. W., Koch, K., Yousefi, S., and VanderElst, I. Growth inhibition of human melanoma tumor xenografts in athymic nude mice by swainsonine. Cancer Res., 50: 1867-1872, 1990.
28. Oredipe, O. A., White, S. L., Grzegorzewski, K., Gause, B. L., Cha, J. K., Miles, V. A., and Olden, K. Protective effects of swainsonine on murine survival and bone marrow proliferation during cytotoxic chemotherapy. J. Natl. Cancer Inst., 83: 1149-1156, 1991.
29. White, S. L., Nagai, T., Akiyama, S. K., Reeves, E. J., Grzegorzewski, K., and Olden, K. Swainsonine stimulation of the proliferation and colony forming activity of murine bone marrow. Cancer Commun., 3: 83-91, 1991.
30. k) expression, and interleukin-1 production by swainsonine. Cancer Commun., 1: 373-379, 1989.
31. Breton, P., Asseffa, A., Grzegorzewski, K., Akiyama, S. K., White, S. L., Cha, J. K., and Olden, K. Swainsonine modulation of protein kinase C activity in murine peritoneal macrophages. Cancer Commun., 2: 333-338, 1990.
32. Yagita, M., and Saksela, E. Swainsonine, an inhibitor of glycoprotein processing, enhances cytotoxicity of large granular lymphocytes. Scand. J. Immunol., 31: 275-282, 1990.
33. Goss, P. E., Baptiste, J., Fernandes, B., Baker, M., and Dennis, J. W. A Phase I study of swainsonine in patients with advanced malignancies. Cancer Res., 54: 1450-1457, 1994.
34. Baptista, J. A., Goss, P., Nghiem, M., Krepinsky, J. J., Baker, M., and Dennis, J. W. Measuring swainsonine in serum of cancer patients: Phase I clinical trial. Clin. Chem., 40: 426-430, 1994.
35. Cummings, R. D., and Kornfeld, S. Characterization of the structural determinants required for the high affinity interaction of asparagine-linked oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating and erthroagglutinating lectins. J. Biol. Chem., 257: 11230-11234, 1982.
36. Tulsiani, D. R., Harris, T. M., and Touster, O. Swainsonine inhibits the biosynthesis of complex glycoproteins by inhibition of Golgi mannosidase II. J. Biol. Chem., 257: 7936-7939, 1982.
37. De Gasperi, R., Daniel, P. F., and Warren, C. D. A human lysosomal α-mannosidase specific for the core of complex glycans. J. Biol. Chem., 267: 9706-9712, 1992.
38. Taylor, M. E., Conary, J. T., Lennartz, M. R., Stahl, P. D., and Drickamer, K. Primary structure of the mannose receptor contains multiple motifs resembling carbohydrate recognition domains. J. Biol. Chem., 205: 12156-12162, 1990.
39. Chung, K. N., Sheperd, V. L., and Stahl, P. D. Swainsonine and castanospermine blockade of mannose glycoprotein uptake by macrophages. Apparent inhibition of receptor-mediated endocytosis by endogenous ligands. J. Biol. Chem., 259: 14637-14641, 1984.
40. Tulsiani, D. R., and Touster, O. Swainsonine, a potent mannosidase inhibitor, elevates rat liver and brain lysosomal α-D-mannosidase, decreases Golgi-α-D-mannosidase II, and increases the plasma levels of several acid hydrolases. Arch. Biochem. Biophys., 224: 594-600, 1983.
41. Colombo, M. P., Modesti, A., Parmiani, G., and Forni, G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res., 52: 4853-4857, 1992.
42. Margolin, K. A., Rayner, A. A., Hawkins, M. J., Atkins, M. B., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Doroshow, J. H., Jaffe, H. S., Roper, M., Parkinson, D. R., Wiernik, P. H., Creekmore, S. P., and Boldt, D. H. Interleukin-2 and lymphokine activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J. Clin. Oncol., 7: 486-498, 1989.
43. Thompson, J. A., Lee, D. J., Cox, W. W. Lindgren, C. G., Collins, C., Neraas, K. A., Dennin, R. A., and Fefer, A. Recombinant interleukin-2 toxicity, pharmacokinetics, and immunomodulatory effects in a Phase I trial. Cancer Res., 47: 4202-4207, 1987.
44. Tulsiani, D. R., Broquist, H. P., James, L. F., and Touster, O. The similar effects of swainsonine and locoweed on tissue glycosidases and oligosaccharides of the pig indicate that the alkaloid is the principal toxin responsible for the induction of locoism. Arch. Biochem. Biophys., 232: 76-85, 1984.
45. Pritchard, D. H., Huxtable, C. R., Dorling, D. R., and Colegate, S. M. The effect of swainsonine on the growth rate of young rats. In: L. F. James, A. D. Elbein, R. J. Molyneux, and C. D. Warren (eds.), Swainsonine and Related Glycosidase Inhibitors. Ames, Iowa: Iowa State University Press, 360-366, 1987.
46. Lemaire, S., Derappe, C., Michalski, J. C., Aubry, M., and Neel, D. Expression of β1-6 N-linked oligosaccharides is associated with activation in human T4 and T8 cell populations. J. Biol. Chem., 269: 8069-8074, 1994.
47. Das, P. C., Roberts, J. D., White, S. L., and Olden, K. Activation of resident tissue-specific macrophages by swainsonine. Oncology Res., 7: 425-433, 1995.